NPM1 and myelodysplastic syndrome: Accordingly, due to the lack of prognostic significance of multilineage dysplasia in patients without MDS-associated cytogenetic findings and with a mutation of NPM1 or biallelic mutation of CEBPA, the revised WHO 2016 classification of myeloid neoplasms defined that these genetic lesions now supersede the morphological presence of multilineage dysplasia in the diagnostic classification [21].